InSimo
Financials
Estimates*
EUR | 2014 | 2015 | 2023 |
---|---|---|---|
Revenues | 1.0m | <1m | 2.4m |
% growth | - | (7 %) | - |
EBITDA | - | <1m | - |
% EBITDA margin | - | 27 % | - |
Profit | <1m | <1m | - |
% profit margin | 51 % | 41 % | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
€410k | Grant | ||
Total Funding | €410k |
Related Content
Recent News about InSimo
EditInSimo is a pioneering company in the field of medical simulation, specializing in biomechanical simulation software that replicates the realistic and interactive behavior of organs and surgical procedures. Operating primarily in the healthcare and medical education markets, InSimo serves a diverse range of clients including medical schools, hospitals, and specialized training centers. The company’s business model revolves around the development and licensing of custom simulation solutions tailored to the specific needs of its clients. By leveraging cutting-edge technology and maintaining close relationships with the academic community, InSimo ensures that its products are both innovative and highly relevant to current medical practices. Revenue is generated through software licensing, custom development projects, and ongoing support services.
Keywords: Biomechanical simulation, medical training, surgical procedures, healthcare education, custom solutions, software licensing, academic partnerships, cutting-edge technology, realistic simulations, professional standards.